Substitution therapy | Virtual Summit 2020

Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor therapies, FVIII-based immune tolerance induction (ITI) is still the only effective means to inhibitor eradication. With the recently introduced Atlanta protocol, emicizumab prophylaxis is given in combination with 50-100 IU/kg FVIII three times a week. […]

Non-factor Replacement Hemophilia Therapies

Adapted from: Global NMO Training 2018 plenary presentation by Glenn Pierce Reviewed by: Glenn Pierce Edited by: Georghia Michael The learner is strongly advised to complete Module 1 Introduction to Bleeding Disorders and Module 2 Evolution of Treatment Products, in the WFH Treatment Products eLearning Program before embarking upon Module 4. This fourth module in […]